Fig. 5.

TMAO increases the levels of senescence-related markers and ROS accumulation in mice. A and B p16 and p21 immunostaining in abdominal aortae from mice after AngII or PBS treatment. Bar = 100 μm. C Densitometry of p16 and p21 contents (n = 6). D Western blotting and analysis of p16 and p21 in mice after AngII or PBS treatment (n = 3). E The level of ROS in the abdominal aortas of AngII- and PBS-infused mice was evaluated by dihydroethidium (DHE) staining (scale bars, 100 µm). F and G p16 and p21 immunostaining in abdominal aortae from mice after CaCl₂ or PBS treatment. Bar = 100 μm. H Densitometry of p16 and p21 contents after CaCl₂ or PBS treatment (n = 6). I Western blotting and analysis of p16 and p21 in mice after CaCl₂ or PBS treatment (n = 3). J The level of ROS in the abdominal aortas of CaCl₂- and PBS-infused mice was evaluated by dihydroethidium (DHE) staining (scale bars, 100 µm)